Velorum Therapeutics Inc.

Plano, TX

UEI
MTV1VNACTWS9
CAGE
9LLD9
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Minority Owned Business
  • For Profit Organization
  • Other Than One of the Proceeding
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
4665 Sundance Dr, Plano, TX 75024, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Velorum Therapeutics Inc.'s latest federal award, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
VEL-03: IND-enabling development of a novel therapeutic approach for treatment of non-small cell lung cancer and other… Grant · R44CA291444 National Cancer Institute $2,030,638

Quick answers

What is Velorum Therapeutics Inc.'s UEI?

Velorum Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is MTV1VNACTWS9.

What is Velorum Therapeutics Inc.'s CAGE code?

Velorum Therapeutics Inc.'s CAGE code is 9LLD9.

What is Velorum Therapeutics Inc.'s primary NAICS code?

Velorum Therapeutics Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Velorum Therapeutics Inc. located?

Velorum Therapeutics Inc.'s physical address in SAM.gov is 4665 Sundance Dr, Plano, TX 75024, USA.

Is Velorum Therapeutics Inc. registered in SAM.gov?

Yes. Velorum Therapeutics Inc.'s SAM.gov registration is active through April 7, 2027.

What is Velorum Therapeutics Inc.'s most recent federal award?

Velorum Therapeutics Inc.'s most recent federal grant award is VEL-03: IND-enabling development of a novel therapeutic approach for treatment of non-small cell lung cancer and other… (R44CA291444), from National Cancer Institute, on June 3, 2025.

On GovTribe

See Velorum Therapeutics Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors